---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-004899"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2026-01-16T23:59:59+00:00"
generated_at: "2026-05-16T09:55:02.444224+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics Files Presentation Materials for Weight Loss Drug and Pipeline Meetings with US Officials

## Summary
- Prepared presentation for US government officials on weight loss drug HT-VA and broader therapeutics pipeline
- HT-001 for skin toxicity from cancer therapy: Phase 2a data and full PK dataset expected Q1 2026
- HT-KIT targeting mastocytosis and KIT-driven cancers: IND submission targeted for Q4 2026
- HT-ALZ Alzheimer's program: preclinical data showing improved memory and reduced neuroinflammation
- HT-VA obesity program licensed from VA; preclinical studies under CRADA initiated Q3 2025

## SEC filing metadata
- accession: 0001213900-26-004899
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2026-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390026004899/0001213900-26-004899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390026004899/ea0272968-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-004899
- JSON: https://secwatch.observer/filing/0001213900-26-004899.json
- Plain text: https://secwatch.observer/filing/0001213900-26-004899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.